Commitments and Contingencies (Details Narrative) |
3 Months Ended | ||||||
---|---|---|---|---|---|---|---|
Nov. 03, 2020 |
Dec. 13, 2019
USD ($)
$ / shares
shares
|
Dec. 13, 2019
EUR (€)
shares
|
Mar. 31, 2021
USD ($)
|
Mar. 31, 2021
EUR (€)
|
Mar. 31, 2021
EUR (€)
|
Dec. 31, 2020
USD ($)
|
|
Total Long-Term Debt | $ 3,231,243 | ||||||
Payments for future research and collobration | 1,100,000 | ||||||
Short term lease costs | 15,647 | ||||||
Aggerate amount payable, description | the Company to pay in aggregate of up to $2.9 million over a period of 22 months. | ||||||
Operating lease right-of-use assets | 303,548 | $ 326,085 | |||||
Operating Lease Right of Use Obligations [Member] | |||||||
Short term lease costs | $ 309,379 | ||||||
Weighted average discount rate | 4.49% | 4.49% | |||||
Weighted average remaining lease term | 29 months | 29 months | |||||
Operating lease right-of-use assets | $ 303,548 | ||||||
Payment of lease liabilities | 21,562 | ||||||
Operating lease expense | 21,488 | ||||||
Managing Director's Agreement [Member] | |||||||
Amount payable | $ 229 | ||||||
Transaction agreement description | In connection with the transaction agreement, the Company also entered into a 2-year Managing Director’s agreement with the founder of Octamer to continue to manage Volition Germany for a payment of €288,000 payable in equal monthly installments over such 2-year period and a royalty agreement with the founder providing for the payment of royalties in the amount of 6% of net sales of Volition Germany’s nucleosomes as reagents to pharmaceutical companies for use in the development, manufacture and screening of molecules for use as therapeutic drugs for a period of 5 years post-closing. | In connection with the transaction agreement, the Company also entered into a 2-year Managing Director’s agreement with the founder of Octamer to continue to manage Volition Germany for a payment of €288,000 payable in equal monthly installments over such 2-year period and a royalty agreement with the founder providing for the payment of royalties in the amount of 6% of net sales of Volition Germany’s nucleosomes as reagents to pharmaceutical companies for use in the development, manufacture and screening of molecules for use as therapeutic drugs for a period of 5 years post-closing. | |||||
Royalty payment | $ 126,829 | ||||||
Royality | 6.00% | 6.00% | |||||
Stock based compensation expenses | $ 753,000 | ||||||
On September 16, 2020 [Member] | Bioinformatic Analytics Of Cell Free DNA [Member] | |||||||
Total long-term debt | 21,482 | ||||||
Repayment of long-term loan amount | € | € 54,879 | ||||||
In 2019 [Member] | Taxes A&M University [Member] | |||||||
Repayment of long-term loan amount | $ 400,000 | ||||||
Loan agreement term | 5 years | 5 years | |||||
Collaborative obligations amount due | $ 235,036 | ||||||
In 2018 [Member] | Long-term Debt [Member] | Loan Agreement [Member] | Namur Innovation and Growth [Member] | |||||||
Total long-term debt | $ 219,184 | ||||||
Repayment of long-term loan amount | € | € 500,000 | ||||||
Loan agreement term | 4 years | 4 years | |||||
Fixed interest rate | 4.00% | 4.00% | |||||
Maturity date | Jun. 30, 2022 | Jun. 30, 2022 | |||||
In 2018 [Member] | Finance Lease Obligations [Member] | BNP Paribas leasing solutions [Member] | |||||||
Purchase price for the property | € | € 25,000 | ||||||
Maturity date | Jan. 31, 2022 | Jan. 31, 2022 | |||||
Amount payable | $ 8,826 | ||||||
Implicit interest | 1.35% | 1.35% | |||||
Leased equipment amortized term | 5 years | 5 years | |||||
October 25, 2019 [Member] | TAMU [Member] | |||||||
Non-controlling interest | 7.50% | 7.50% | |||||
Equity interest | 12.50% | 12.50% | |||||
Additional interest | 5.00% | 5.00% | |||||
January 10, 2020 [Member] | |||||||
Common stock, restricted shares issued in exchange of purchased outstanding shares, value | $ 333,969 | ||||||
Restricted shares issued | shares | 73,263 | 73,263 | |||||
Common stock, restricted shares issued in exchange of purchased outstanding shares, shares | shares | 73,263 | 73,263 | |||||
Weighted trading price per share | $ / shares | $ 4.56 | ||||||
Repayment of debt | € | € 350,000 | ||||||
Common stock adjusted amount | $ 357,000 | ||||||
Holdback period | 9 months | 9 months | |||||
Holdback liabilities | $ 55,404 | ||||||
Net liabilities | $ 43,152 | ||||||
In 2019 [Member] | Collaborative Arrangement, Co-promotion [Member] | |||||||
Collaborative obligations amount due | $ 96,000 | ||||||
Research collaboration agreement description | The Company entered into a research collaboration agreement with the University of Taiwan to collect a total of 1,200 samples for a 2-year period for a cost to the Company of up to $320,000 payable over such period | The Company entered into a research collaboration agreement with the University of Taiwan to collect a total of 1,200 samples for a 2-year period for a cost to the Company of up to $320,000 payable over such period | |||||
ING [Member] | In 2016 [Member] | Long-term Debt [Member] | |||||||
Fixed interest rate on lease | 2.62% | 2.62% | |||||
Lease payable | $ 612,599 | ||||||
Purchase price for the property | € | € 1,120,000 | ||||||
ING [Member] | In 2016 [Member] | Long-term Debt [Member] | Loan Agreement [Member] | |||||||
Total long-term debt | $ 240,838 | ||||||
Repayment of long-term loan amount | € | € 270,000 | ||||||
Loan agreement term | 15 years | 15 years | |||||
Fixed interest rate | 2.62% | 2.62% | |||||
Maturity date | Dec. 31, 2031 | Dec. 31, 2031 | |||||
Namur [Member] | October 13, 2020 [Member] | Long-term Debt [Member] | Loan Agreement [Member] | |||||||
Total long-term debt | $ 974,706 | ||||||
Borrowed amount | € | € 65,453 | ||||||
Repayment of long-term loan amount | € | € 830,000 | ||||||
Loan agreement term | 10 years | 10 years | |||||
Fixed interest rate | 4.00% | 4.00% | |||||
Maturity date | Mar. 31, 2021 | Mar. 31, 2021 | |||||
Namur Invest [Member] | In 2016 [Member] | Long-term Debt [Member] | Loan Agreement [Member] | |||||||
Total long-term debt | $ 238,568 | ||||||
Repayment of long-term loan amount | € | € 440,000 | ||||||
Loan agreement term | 7 years | 7 years | |||||
Fixed interest rate | 4.85% | 4.85% | |||||
Maturity date | Dec. 31, 2023 | Dec. 31, 2023 | |||||
Namur Invest [Member] | In 2019 [Member] | Long-term Debt [Member] | Loan Agreement [Member] | |||||||
Total long-term debt | $ 587,171 | ||||||
Repayment of long-term loan amount | € | € 500,000 | ||||||
Loan agreement term | 4 years | 4 years | |||||
Fixed interest rate | 4.80% | 4.80% | |||||
Maturity date | Sep. 30, 2024 | Sep. 30, 2024 | |||||
Namur Invest [Member] | In 2017 [Member] | Long-term Debt [Member] | Loan Agreement [Member] | |||||||
Total long-term debt | $ 31,302 | ||||||
Repayment of long-term loan amount | € | € 350,000 | ||||||
Loan agreement term | 4 years | 4 years | |||||
Fixed interest rate | 4.00% | 4.00% | |||||
Maturity date | Jun. 30, 2021 | Jun. 30, 2021 | |||||
SOFINEX [Member] | In 2017 [Member] | Long-term Debt [Member] | Loan Agreement [Member] | |||||||
Total long-term debt | $ 939,474 | ||||||
Repayment of long-term loan amount | € | € 1,000,000 | ||||||
Loan agreement term | 7 years | 7 years | |||||
Fixed interest rate | 4.50% | 4.50% | |||||
Maturity date | Sep. 30, 2024 | Sep. 30, 2024 | |||||
Walloon Region Government [Member] | In 2010 [Member] | |||||||
Repayment of long-term loan amount | € | € 315,788 | ||||||
Amount payable | $ 102,645 | ||||||
Grant receivable | € | € 1,050,000 | ||||||
Repayment of grants | € | 314,406 | ||||||
Terms of agreement description | it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €314,406 and the 6% royalty on revenue, is equal to twice the amount of funding received. | it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €314,406 and the 6% royalty on revenue, is equal to twice the amount of funding received. | |||||
Walloon Region Government [Member] | In 2018 [Member] | Colorectal Cancer Research Agreement [Member] | |||||||
Amount payable | $ 213,143 | ||||||
Grant receivable | € | 605,000 | ||||||
Repayment of grants | € | 181,500 | ||||||
Terms of agreement description | It is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received. | It is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received. | |||||
DKFZ [Member] | In 2016 [Member] | Research Co-operation Agreement [Member] | |||||||
Collaborative obligations amount due | $ 234,869 | ||||||
Lease agreement expire period | 5 years | 5 years | |||||
Collaborative obligations amount | € | € 400,000 | ||||||
University of Taiwan [Member] | In 2018 [Member] | Clinical Study Research Agreement [Member] | |||||||
Collaborative obligations amount due | $ 510,000 | ||||||
Lease agreement expire period | 3 years | 3 years | |||||
Collaborative obligations amount | $ 2,550,000 |